H. pylori resistance to clarithromycin doubles in Europe

Over the last 20 years, Helicobacter pylori resistance to clarithromycin — an antibiotic commonly used to treat the infection — has more than doubled in Europe, increasing from 9.9% in 1998 to 21.6% in 2018, according to study findings presented at United European Gastroenterology Week.
“Culture and antimicrobial susceptibility testing are rarely performed, hence regular surveys are important to monitor resistance and infer treatments which can be used,” Francis Mégraud, MD, DPharm, professor of bacteriology at the University of Bordeaux in France, told

Source link

Related posts

Few Published Programs Address Medical Trainee Mistreatment


Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via β-catenin


AMA Urges Caution With Use of Wire-Bristle BBQ Grill Brushes


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy